FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2499190086> ?p ?o ?g. }

• W2499190086 endingPage "CT159" @default.
• W2499190086 startingPage "CT159" @default.
• W2499190086 abstract "Abstract Introduction: Dysregulation in tyrosine kinase signaling has been implicated in development of hematologic malignancies including myelofibrosis and lymphomas. Pacritinib is an oral kinase inhibitor with specificity for JAK2, FLT3, CSF1R, and IRAK1. In mouse distribution studies of radiolabeled pacritinib, ∼91% of administered dose was recovered in the feces, suggesting an important role for biliary elimination in clearance of pacritinib. This phase 1 trial investigated clearance pathways, excretion, pharmacokinetics, and recovery of pacritinib, its major metabolites, and total radioactivity in healthy volunteers. Methods: Healthy male volunteers aged 18-55 y were eligible for inclusion. Study volunteers received a single 400 mg dose of pacritinib capsules plus a single dose of [14C]-pacritinib (100 μCi radioactivity per &lt;1 mg of pacritinib as a 30 mL suspension). Blood, urine, and feces were sampled predose and up to 42 days postdose. Pacritinib and metabolites were identified using HPLC-MS/MS/radio flow-through detector (RFD), high resolution mass spectrometry, and authentic metabolite standards. Results: Six subjects were enrolled and received [14C]-pacritinib. Peak radioactivity in plasma was reached approximately 2 h following administration. Mean apparent volume of distribution and apparent clearance in plasma were 137 L and 1.73 L/h, respectively. Elimination half-life for total radioactivity in plasma was 55.1 h. Twelve pacritinib metabolites were identified: M1, M2, M3, M5, M6, M7, M8, M9, M12, M13, M14, and M14a and reflected metabolic pathways including oxidation, N-dealkylation, O-dealkylation, hydrolysis, and dehydrogenation. Pacritinib was the predominant radioactive component (72%) recovered in plasma from 0.5-120 h with mean maximum concentration (Cmax) of 4117.2 ng/mL. Mean Cmax for M2, M1, M3, and M8 were 887.0, 854.5, 292.3, and 148.6 ng/mL respectively. Mean metabolite exposure ratios for major metabolites, M1 and M2, in plasma relative to pacritinib were 0.0963 and 0.105, respectively. Mean recovery of radioactivity in urine (0-48 h) was 3.22% of administered dose; M7, a glucuronidated metabolite, was the predominant radioactive component (3.03% of administered dose). Pacritinib recovered in urine accounted for 0.12% of administered dose. From 0-240 h postdose, mean recovery of radioactivity in feces was 85.5% of administered dose. Pacritinib was detected by MS in fecal samples, but not by RFD. Metabolite M2 was the predominant radioactive fecal component, (24.1% of administered dose). Five individuals (83.3%) reported 9 total adverse events (AEs); all AEs were grade 1 and included diarrhea (5 events in 4 individuals) and nausea (1 event in 1 individual). There were no clinically significant abnormalities in vital signs, ECG, or by physical examination. Conclusions: Following oral administration, pacritinib was the predominant moiety recovered in plasma. Pacritinib was extensively metabolized; major metabolites (M1, oxidation; M2, dealkylation) have relatively low pharmacological potency and are unlikely to substantially contribute to the activity of pacritinib. Intact pacritinib was minimally excreted in urine and feces. Most radioactivity was recovered as metabolites in feces, suggesting extensive biliary clearance and hepatic metabolism of pacritinib. Citation Format: Suliman Al-Fayoumi, Sherri Amberg, Huafeng Zhou, Lindsey Millard, Jack W. Singer, James P. Dean. Investigation of the absorption, metabolism, excretion, and mass balance of [14C]-pacritinib in healthy subjects: a phase I study. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr CT159." @default.
• W2499190086 created "2016-08-23" @default.
• W2499190086 creator A5002064171 @default.
• W2499190086 creator A5005050727 @default.
• W2499190086 creator A5015287057 @default.
• W2499190086 creator A5045366442 @default.
• W2499190086 creator A5080985964 @default.
• W2499190086 creator A5089625305 @default.
• W2499190086 date "2016-07-15" @default.
• W2499190086 modified "2023-09-28" @default.
• W2499190086 title "Abstract CT159: Investigation of the absorption, metabolism, excretion, and mass balance of [14C]-pacritinib in healthy subjects: a phase I study" @default.
• W2499190086 doi "https://doi.org/10.1158/1538-7445.am2016-ct159" @default.
• W2499190086 hasPublicationYear "2016" @default.
• W2499190086 type Work @default.
• W2499190086 sameAs 2499190086 @default.
• W2499190086 citedByCount "1" @default.
• W2499190086 countsByYear W24991900862022 @default.
• W2499190086 crossrefType "journal-article" @default.
• W2499190086 hasAuthorship W2499190086A5002064171 @default.
• W2499190086 hasAuthorship W2499190086A5005050727 @default.
• W2499190086 hasAuthorship W2499190086A5015287057 @default.
• W2499190086 hasAuthorship W2499190086A5045366442 @default.
• W2499190086 hasAuthorship W2499190086A5080985964 @default.
• W2499190086 hasAuthorship W2499190086A5089625305 @default.
• W2499190086 hasConcept C10146269 @default.
• W2499190086 hasConcept C112705442 @default.
• W2499190086 hasConcept C126322002 @default.
• W2499190086 hasConcept C134018914 @default.
• W2499190086 hasConcept C185592680 @default.
• W2499190086 hasConcept C2777477808 @default.
• W2499190086 hasConcept C2780026642 @default.
• W2499190086 hasConcept C62231903 @default.
• W2499190086 hasConcept C71924100 @default.
• W2499190086 hasConcept C98274493 @default.
• W2499190086 hasConceptScore W2499190086C10146269 @default.
• W2499190086 hasConceptScore W2499190086C112705442 @default.
• W2499190086 hasConceptScore W2499190086C126322002 @default.
• W2499190086 hasConceptScore W2499190086C134018914 @default.
• W2499190086 hasConceptScore W2499190086C185592680 @default.
• W2499190086 hasConceptScore W2499190086C2777477808 @default.
• W2499190086 hasConceptScore W2499190086C2780026642 @default.
• W2499190086 hasConceptScore W2499190086C62231903 @default.
• W2499190086 hasConceptScore W2499190086C71924100 @default.
• W2499190086 hasConceptScore W2499190086C98274493 @default.
• W2499190086 hasIssue "14_Supplement" @default.
• W2499190086 hasLocation W24991900861 @default.
• W2499190086 hasOpenAccess W2499190086 @default.
• W2499190086 hasPrimaryLocation W24991900861 @default.
• W2499190086 hasRelatedWork W1964713169 @default.
• W2499190086 hasRelatedWork W1969516443 @default.
• W2499190086 hasRelatedWork W1982018239 @default.
• W2499190086 hasRelatedWork W1997230207 @default.
• W2499190086 hasRelatedWork W2064103176 @default.
• W2499190086 hasRelatedWork W2233766350 @default.
• W2499190086 hasRelatedWork W2263695696 @default.
• W2499190086 hasRelatedWork W2550782658 @default.
• W2499190086 hasRelatedWork W2556046137 @default.
• W2499190086 hasRelatedWork W2739477796 @default.
• W2499190086 hasRelatedWork W2890987200 @default.
• W2499190086 hasRelatedWork W2908935613 @default.
• W2499190086 hasRelatedWork W2936141205 @default.
• W2499190086 hasRelatedWork W3047449617 @default.
• W2499190086 hasRelatedWork W3091947663 @default.
• W2499190086 hasRelatedWork W3161188679 @default.
• W2499190086 hasRelatedWork W3182683516 @default.
• W2499190086 hasRelatedWork W3201862884 @default.
• W2499190086 hasRelatedWork W2183354313 @default.
• W2499190086 hasRelatedWork W2189113978 @default.
• W2499190086 hasVolume "76" @default.
• W2499190086 isParatext "false" @default.
• W2499190086 isRetracted "false" @default.
• W2499190086 magId "2499190086" @default.
• W2499190086 workType "article" @default.